The variability in treatment responses observed among distinct PTCL subtypes may be attributed to differences in the baseline activation levels of the mTOR signaling pathway, which constitutes a principal therapeutic target of everolimus. This evidence concerns the gene MTOR and mature T-cell and NK-cell non-Hodgkin lymphoma.